SEC Filing Summary: Inhibrx Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
Inhibrx Biosciences, Inc. (INBX), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on May 14, 2026. The filing serves to announce the Company's financial results for the three months ended March 31, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) referenced in Item 2.02 but are not included in the text of the 8-K itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include specific management commentary, forward-looking guidance, risk factors, or details on unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q1 2026 financial figures including net loss, cash position, and operating expenses.
- Verify the Company's cash runway and burn rate as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.